Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A total of 91 patients with stage I endometrial adenocarcinoma who were referred for radiation prior to hysterectomy were randomly allocated to recieve either intracavitary or external bean irradiation. Total abdominal hysterectomy was done 4-8 weeks later. The 53 patients who received intracavitary irradiation had an actuarial 5 year disease-free survival rate of 75%; the survival rate of the 38 patients in the external beam group was 48%. Nine patients in the external beam group had recurrence or metastases compared to two in the intracavitary group. These recurrences were predominantly pelvic. Complications were also more frequent in the external beam group. These results demonstrate that intracavitary radiation is superior to external beam radiation using the regiments described.
 ...
PMID:Preoperative radiation therapy in endometrial carcinoma: preliminary report of a clinical trial. 18 14

Carcinoembryonic antigen was determined before treatment in 101 patients with adenocarcinoma of the uterus. If 2.5 ng/ml is accepted as the upper normal value, 34% of the patients with cancer of the corpus had elevated levels. Only 7% had values exceeding 5 ng/ml. The highest recorded value in endometrial carcinoma was 8.5 ng/ml. In adenocarcinoma of the cervix 68% had values over 2.5 ng/ml and a direct correlation between nodal metastases and plasma elevation of CEA was found. The highest recorded value for endocervical cancer was 108 ng/ml. No patient with localized disease had a value over 4.0 ng/ml. It is concluded that adenocarcinomas of the cervix and corpus have different biological properties, and that in adenocarcinoma of the cervix determination of CEA is a reliable indicator of the extent of disease.
 ...
PMID:Studies on carcinoembryonic antigen levels in patients with adenocarcinoma of the uterus. 58 61

Of 617 patients receiving initial therapy for endometrial adenocarcinoma from 1949 to 1965, 90 patients were retrospectively assigned to Stage II (FIGO) by reviewing preoperative, operative, and pathologic findings. In 66 patients (73%) the cervical spread of endometrial cancer was occult and detected only microscopically in the hysterectomy specimen, whereas in the other 24 (27%) it was detected clinically prior to surgery. The survival rate for patients with occult cervical involvement was better (61%) than in those patients with gross cervical spread of tumor (48%), but the difference was not statistically significant. When the surgical specimen revealed that the only spread was to the cervix, those having only occult spread had a better 5-year corrected survival rate (89%) than those with grossly detectable spread (57%). Spread of tumor beyond the uterus occurred in over one-third of the patients with each kind of cervical spread. Study of lymphadenectomy specimens in 31 patients revealed a similar incidence of lymph node metastases for both groups: 25% in those with grossly detectable spread and 21% in those with occult spread. Only 1 of the 7 patients with positive pelvic lymph nodes had clinically positive paraaortic nodes in addition to the positive pelvic nodes. Thus, only 1 of the 31 patients having the stnadard pelvic lymph node dissection was found to have paraaortic metastasis, as it was routine to sample only clinically positive paraaortic lymph nodes. These data suggest that in Stage II endometrial adenocarcinoma both gross and occult cervical involvement have a relatively bad prognosis and require aggressive therapy.
 ...
PMID:Stage II endometrial adenocarcinoma. Memorial Hospital for Cancer, 1949-1965. 85 May 78

This is a case report of endometrial adenocarcinoma in a patient with Turner's syndrome who had received estrogen-progestogen therapy for 13 years. At age 22 she was treated for primary amenorrhea and absence of secondary sexual characteristics. Urinary gonadotropin assay exceeded 32 mouse units/24 hours and infantile external genitalia, uterine hypoplasia, and impalpable ovaries were found. Cytogenetic studies confirmed a 45XO karyotype. For 13 years she received stilbestrol cyclically for 21 days with ethisterone, 5 mg twice daily, added for Days 16-21 of each cycle. Secondary sexual characteristics developed. After 13 years anemia developed, the uterus was found to be the size of a 20-week pregnancy, and an endometrial polyp protruding through the cervix showed squamous metaplasia. Following hysterectomy, histologic studies showed well-differentiated adenocarcinoma of the endometrium with some squamous metaplasia and osteoid formation. Metastases were not found. Similar cases treated with stilbestrol alone have been reported. Genetic predisposition is possible with this patient's X chromosome abnormality. However, estrogen therapy is thought to be a causative factor. Those receiving such therapy should have periodic gynecological examinations with curettage even when progestogens are also being used.
 ...
PMID:Endometrial carcinoma after cyclical oestrogen-progestogen therapy for Turner's syndrome. 113 7

A 46-year-old nulligravida complained of the recent development of an erythematous skin eruption and fine blond hair over her face. These complaints appeared to be symptoms of acquired hypertrichosis lanuginosa, which may be associated with malignancy. The patient was found to have an endometrial adenocarcinoma with nodal metastases and was treated with hysterectomy and irradiation. Eighteen months later there was no evidence of the cancer, and the lanugo hairs had vanished. This is the first known instance of hypertrichosis lanuginosa associated with a gynecologic cancer and the first ever observed in which the lanugo hairs disappeared after cancer therapy.
 ...
PMID:Acquired hypertrichosis lanuginosa associated with endometrial malignancy. 125 31

Human endometrial adenocarcinoma cells (Ishikawa line) constitutively express c-erbB2 coded oncoprotein p185erbB2 (p185) which is believed to be an orphan receptor for an unknown growth factor. Since we have shown that expression of p185 in primary lesions of endometrial cancer correlates well with high frequency of lymph node++ metastases and that the metastatic cells in the nodes strongly expressed p185, the role of the oncoprotein in processes of metastases was studied. Culturing the cells in the presence of 15% FCS and with monoclonal antibody to the extracellular domain of p185 (CB-1) inhibited cell growth and attenuated p185 expression on Western blotting, whereas no change occurred with the control antibody. Cells cultured without FCS achieved only approximately 1/3 growth compared to cells with FCS, and further suppression of growth was observed after adding CB-1. When cells were cultured on human term amnion, basement membrane invasion with p185 expression was observed. In nude mice, intraperitoneal seeding resulted in implant formation which was also associated with positive p185 as well as cyclin immunohistochemistry. In the two experiments, treatment of cells with CB-1 inhibited invasion or implant formation. The present study suggests that a signal through p185 receptor molecules acts as a trigger for early proliferation, and interaction with the host may enhance up-regulation of p185.
 ...
PMID:[Role of p185c-erbB2 in endometrial cancer growth in vitro]. 135 38

From 1976 to 1981, 171 patients with stage I endometrial adenocarcinoma (FIGO, 1971) underwent intracavitary radiotherapy alone because of medical contraindications to surgery and external-beam irradiation. The mean age of patients was 71 years, with the majority of patients being in the age group of 70-79 years. The intracavitary therapy consisted of intrauterine insertions of radium implants in three consecutive courses according to the packing method of Heyman. The estimated dose delivered to point A and to point B was 80 and 20 Gy (3500-7000 mg-hr; mean, 5500 mg-hr), respectively. The corrected 5-year survival rate for stage Ia was 76% and for stage Ib 72%. Grade had a profound effect on survival; corrected 5-year survival for G1 was 77%, for G2 68%, and for G3 53%, respectively. The total failure rate was 24% (40/171). Most of the recurrences occurred in the pelvis (35/171): uterus, 22; vagina, 9; rectum, 2; and bladder, 1. One patient had both vaginal and uterine failure and five had distant metastases (four abdominal and one pulmonary). No difference was seen in the failure rates of stage Ia and stage Ib patients. No major complications (necessitating hospital care or delay of treatment) were seen. Our findings suggest that for patients with stage I endometrial cancer who are unfit for surgery, intracavitary low-dose-rate radiation therapy alone is an effective alternative treatment with a low risk of complications.
 ...
PMID:Stage I endometrial carcinoma: treatment of nonoperable patients with intracavitary radiation therapy alone. 175 89

The present study evaluates the effects of various prognostic indicators on survival of patients with clinical Stage I endometrial carcinoma. Ninety-three patients who were treated for clinical Stage I endometrial adenocarcinoma at Maimonides Medical Center from October 1979 to October 1987 had sufficient surgical-pathological information for retrospective surgical staging according to the new FIGO classification. Histology was reviewed. A new grade and surgical stage was assigned to each patient in accordance with the recent FIGO guidelines for surgical staging of corpus cancer. Poor prognostic indicators, namely, tumor grade, depth of myometrial invasion, peritoneal cytology, lymph node metastases, and lymphvascular space (LVS) involvement, were correlated with 5-year survival rates. Survival rates were calculated by the life table method. Depth of myometrial invasion, lymph node involvement, and peritoneal cytology had significant statistical correlation with poor survival. Positive finding of each of the prognostic indicators, including LVS involvement, was significantly associated with poor survival (all P less than 0.001). The value of these prognostic indicators in early endometrial carcinoma is discussed.
 ...
PMID:Lymphvascular space involvement--a prognostic indicator in endometrial adenocarcinoma. 189 73

Total hysterectomy with bilateral salpingo oophorectomy is the traditional treatment for endometrial carcinoma. In an effort to improve local control rates, we have surgically treated our Stage I and II patients with radical hysterectomy and pelvic lymphadenectomy (RH-PL). Between 1976 and 1987 we have treated 179 patients with endometrial adenocarcinoma (125 Stage I and 54 Stage II) with the following modalities. Uterovaginal brachytherapy (60 Gy) was performed first and then 6 weeks later an RH-PL was performed. Twenty-nine patients received external pelvic irradiation (45 Gy) because of tumor invasion beyond the internal two-thirds of the myometrium and/or lymph node involvement. The local control rate was 87% (92% for Stage I, 76% for Stage II). Distant metastases occurred in 24 patients (13%). Five-year actuarial survival rates were 80% for Stage I and 61% for Stage II patients. Prognostic factors were nodal status, histological grading, depth of tumor myometrial invasion, histologic status of the hysterectomy specimen, and peritoneal cytology. Late severe complications occurred for 13 patients (7%). These results are comparable to those published for patients treated with less extensive surgery. We conclude that such an extensive surgery (especially pelvic lymphadenectomy) appears to be useless for all patients with bad prognostic factors requiring pelvic external irradiation. We only still perform external iliac node samples for patients with Stage I grade 1 tumors without deep tumor invasion into the myometrium.
 ...
PMID:Radical hysterectomy for stage I and II endometrial carcinoma: a retrospective analysis of 179 cases. 200 43

7 cases of serous-papillary adenocarcinoma of the endometrium (UPSC) were found in a retrospective study of 80 patients which were treated at the Department of Gynaecology of the University of Munich from August 1987 to December 1989 because of endometrial adenocarcinoma. Characteristic histologic findings and prognostic factors of the UPSC were examined by means of large scale sections of the completely worked-up uteri and compared with the usual adenocarcinoma of the endometrioid type (UEC). Despite only minimal myometrial infiltration in some cases, lymphangiosis carcinomatosa was almost always present (6/7) and more than 50% of patients showed evidence of blood vessel involvement. In all patients with pelvic lymph node dissection metastases were found. According to our results in line with the literature, UPSC is a highly malignant and morphologically distinct variant of endometrial adenocarcinoma without promising treatment to date.
 ...
PMID:[Serous papillary adenocarcinoma of the endometrium]. 202 99


1 2 3 4 5 6 7 8 9 10 Next >>